Abstract
Merck collects all serious adverse events reported for patients receiving its investigational or marketed products, whether or not they are drug related. These are communicated immediately to headquarters and are distributed monthly on a worldwide basis to its medical directors. The practice of reporting these adverse events to drug regulatory agencies has caused problems because many times they are assumed to be adverse drug reactions and not events.
Get full access to this article
View all access options for this article.